Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops clinically compatible therapies based on RNA interference.
Year Established: | 2006 |
Funding: | 12.4 |
Address: | Cequent Pharmaceuticals, Inc. One Kendall Square Building 700, First Floor Cambridge, MA 02139 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 617.995.7941 |
Mail: | info@cequentpharma.com |
Company URL: | http://www.cequentpharma.com |
Cequent Pharmaceuticals, Inc. is a privately-held company developing new biopharmaceutical products based on RNA interference (RNAi).
The Cequent team is comprised of highly motivated and committed scientists and business professionals. Our people make the biggest impact in delivering transformational medicine.
If you are interested in opportunities at Cequent, please forward your CV or resume to careers@cequentpharma.com.
Opportunities at Cequent
Come and join a dynamic team of scientists and business leaders to develop a breakthrough novel technology for developing RNAi-based therapies.
If you are interested in potential openings, please submit your CV or resume for consideration. If your background and skills match an open or upcoming position, a representative from Cequent will contact you. Thank you for your interest in joining the Cequent team.
Cequent works only directly with potential candidates, please no third party recruiting inquiries.
Â
Cequent Begins Chronic Toxicology Study with CEQ508, Lead Oncology tkRNAi Drug Candidate; Also Initiates First NHP Toxicology Study of Novartis-Optioned IBD Drug Candidate
Â
MDRNA, Inc. Acquires Cequent Pharmaceuticals, Inc.
Â
FDA Grants Cequent IND
Ampersand Ventures,New England Partners,Novartis Venture Fund (FKA: Novartis Corp.),Pappas Ventures
Peter Parker
President, CEO
Lisa Velardo
CFO
Ted Hibben
Chief Business Officer